ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas-Reference-Cited by-同舟云学术

ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas

Published:2013-09-12 Issue:9 Volume:14 Page:18824-18849
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Samartzis Eleftherios,Noske Aurelia,Dedes Konstantin,Fink Daniel,Imesch Patrick

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/14/9/18824/pdf

Reference163 articles.

1. Mutations and deletions of arid1a in breast tumors;Cornen;Oncogene,2012

2. Emerging epigenetic targets and therapies in cancer medicine;Popovic;Cancer Discov,2012

3. A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

4. Arid1a mutations in endometriosis-associated ovarian carcinomas;Wiegand;N. Engl. J. Med,2010

5. Frequent mutations of chromatin remodeling gene arid1a in ovarian clear cell carcinoma;Jones;Science,2010

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression patterns of HDAC6 in correlation to ARID1A status in different subtypes of endometriosis: A retrospective tissue microarray analysis;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-11

2. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

3. The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis;British Journal of Cancer;2024-07-13

4. Natural Compounds for Preventing Age-Related Diseases and Cancers;International Journal of Molecular Sciences;2024-07-09

5. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL;Blood Cancer Journal;2024-06-20